WO2024254941A1 - 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用 - Google Patents

敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用 Download PDF

Info

Publication number
WO2024254941A1
WO2024254941A1 PCT/CN2023/108489 CN2023108489W WO2024254941A1 WO 2024254941 A1 WO2024254941 A1 WO 2024254941A1 CN 2023108489 W CN2023108489 W CN 2023108489W WO 2024254941 A1 WO2024254941 A1 WO 2024254941A1
Authority
WO
WIPO (PCT)
Prior art keywords
ampk
slc35f6
alpp
knocking down
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/108489
Other languages
English (en)
French (fr)
Inventor
松阳洲
朱建熹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Publication of WO2024254941A1 publication Critical patent/WO2024254941A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Definitions

  • the present application relates to the field of biotechnology, and in particular to the use of an agent for knocking down or inhibiting SLC35F6 in the preparation of a drug for activating AMPK.
  • AMPK Addenosine 5'-monophosphate (AMP)-activated protein kinase
  • AMPK is an AMP-dependent protein kinase, a key molecule for regulating biological energy metabolism. It is a protein molecule widely present in animal and plant cells and is the core of the study of diabetes and other metabolism-related diseases. It is expressed in various metabolism-related organs and can be activated by various stimuli in the body, including cell stress, exercise, and many hormones and substances that can affect cell metabolism.
  • AMPK can sense the level of ATP in cells. When mitochondria are inhibited and low energy supply is provided, AMPK phosphorylates specific enzymes and sites, increases ATP production, and reduces ATP consumption, thereby restoring energy balance.
  • AMPK is the most important kinase in metabolic regulation. When there is a lack of energy in the cell, AMPK is activated by phosphorylation by upstream kinases, and then phosphorylates many key enzymes and control proteins in metabolism, promotes catabolism, inhibits anabolism, increases the accumulation of ATP, and provides energy for cells.
  • the traditional view is that the activation of AMPK is due to the increase in the concentration of intracellular AMP, which binds to the ⁇ subunit of AMPK, changes the conformation of the AMPK heterotrimer, and enables the T172 site of its ⁇ subunit to be phosphorylated by the upstream kinase LKB1, thereby activating the AMPK holoenzyme.
  • AMPK can be activated on lysosomes, and its lysosomal localization depends on the myristoylation modification of the second glycine of the AMPK ⁇ subunit.
  • AMPK on lysosomes can also respond to changes in the concentration of FBP (fructose-1,6-bisphosphate), a secondary product of sugar metabolism. It is still unknown what proteins on lysosomes regulate AMPK activity and whether these proteins can serve as potential drug targets to affect AMPK activity.
  • FBP fructtose-1,6-bisphosphate
  • the regulatory mechanisms based on existing AMPK activators are mainly focused on increasing the phosphorylation of AMPK ⁇ , and the regulatory sites involved are already saturated. There is currently no mechanism for AMPK dephosphorylation to explore and discover AMPK inhibitors and activators.
  • the purpose of the present application is to overcome the deficiencies of the prior art and provide the use of a reagent for knocking down or inhibiting SLC35F6 in the preparation of a drug for activating AMPK.
  • the technical solution adopted by this application is: the application of SLC35F6 in the preparation of AMPK activity inhibitors.
  • the purpose of this application is to explore the lysosomal activation mechanism of AMPK, and then discover new AMPK activity regulatory proteins. Studies have shown that AMPK on lysosomes can sense changes in secondary products of sugar metabolism, which is different from the regulation of AMPK activity in the whole cell. Therefore, there should be new AMPK regulatory proteins on lysosomes that can more directly regulate AMPK activity.
  • This application uses BiFC and proximity labeling technology to discover that the SLC35F6-ALPP complex inhibits the activity of AMPK on lysosomes, and the ligand UDP-GlcNAc of SLC35F6 can relieve the inhibition of AMPK by the SLC35F6-ALPP complex, thereby activating AMPK and exerting therapeutic effects.
  • the present application also provides the use of an agent for knocking down or inhibiting SLC35F6 in the preparation of a drug for activating AMPK.
  • the reagent includes siRNA that knocks down the expression of the SLC35F6 gene.
  • nucleotide sequence of the siRNA is shown in any one of SEQ ID NO.1 to SEQ ID NO.3.
  • the present application also provides the use of an agent for knocking down or inhibiting ALPP in the preparation of a drug for activating AMPK.
  • the reagent includes siRNA that knocks down the expression of ALPP gene.
  • nucleotide sequence of the siRNA is shown in any one of SEQ ID NO.4 to SEQ ID NO.6.
  • the present application also provides an AMPK activator, which includes at least one of an agent for knocking down SLC35F6 and an agent for knocking down ALPP.
  • the present application also provides the use of at least one of an agent for knocking down SLC35F6 and an agent for knocking down ALPP in the preparation of a product for preventing and/or treating tumors, inflammation or diabetes.
  • the reagent includes UDP-GlcNAc.
  • the present application provides the use of a reagent for knocking down or inhibiting SLC35F6 in the preparation of a drug for activating AMPK.
  • the inventors of the present application have found that SLC35F6 can be used as a new target for regulating AMPK activity, and through further research, they have found that the SLC35F6-ALPP complex inhibits AMPK activity on lysosomes.
  • the present application found that knocking down SLC35F6 or ALPP can activate AMPK.
  • appropriate siRNA was selected to efficiently knock down SLC35F6 or ALPP, providing a new technical solution for the activation of AMPK.
  • the present application clarified for the first time the regulatory effect of SLC35F6 on AMPK activity, providing a new approach to the development of preventive and therapeutic drugs and drug targets for the diagnosis and treatment of diseases related to AMPK activity, and having very important medicinal value.
  • FIG1 is a graph showing the expression results of p-AMPK, AMPK, SLC35F6, and tubulin after knocking down SLC35F6 in Example 1;
  • FIG2 is a graph showing the expression results of p-AMPK, AMPK, p-ACC1, ACC1, ALPP, and tubulin after knocking down ALPP in Example 2;
  • FIG3 is a graph showing the expression results of GST, p-AMPK, AMPK, and tubulin in the cell lysate and beads after immunoprecipitation in Example 3;
  • FIG4 is a graph showing the expression results of p-AMPK, AMPK, p-ACC1, ACC1, SLC35F6, and tubulin after knockdown of SLC35F6 and starvation treatment in Example 4;
  • Figure 5 is a graph showing the expression results of p-AMPK, AMPK, p-ACC1, ACC1, SLC35F6, and tubulin after knockdown of SLC35F6 and H 2 O 2 treatment in Example 4;
  • FIG6 is a graph showing the expression results of p-AMPK, AMPK, p-ACC1, ACC1, SLC35F6, and tubulin after SLC35F6 knockdown and AICAR treatment in Example 4.
  • HEK293T cells in good growth condition were added to a six-well plate and cultured at 37°C and 5% CO2 ;
  • siRNAs in the experimental groups were:
  • Experimental group 1 5′-GCAUGGUGUUGGACAGCUU-3′ (SEQ ID NO:1);
  • step (3) The protein obtained in step (3) was subjected to polyacrylamide gel electrophoresis, and the electrophoresis parameters were: constant voltage 80V, 20min plus 120V, 45min, then constant current 0.2A, 1h transfer, and 5% skim milk blocking for 1h; incubated with primary antibodies p-AMPK, AMPK, SLC35F6, tubulin overnight, and then applied with corresponding secondary antibodies the next day to detect the expression level of the corresponding protein.
  • p-AMPK indicates the phosphorylation degree of AMKP, which represents the activity of AMPK.
  • the experimental group did not express SLC35F6, indicating that the experimental group successfully knocked down SLC35F6; the expression of p-AMPK in the control group was lower than that in the experimental group, indicating that AMPK was activated after knocking down SLC35F6.
  • HEK293T cells in good growth condition were added to a six-well plate and cultured at 37°C and 5% CO2 ;
  • Experimental group 1 5′-CUACGCAGCUCAUCUCCAA-3′ (SEQ ID NO:4);
  • step (3) The protein obtained in step (3) was subjected to polyacrylamide gel electrophoresis, and the electrophoresis parameters were: constant voltage 80V, 20min plus 120V, 45min, then constant current 0.2A, 1h transfer, and 5% skim milk blocking for 1h; incubated with primary antibodies p-AMPK, AMPK, p-ACC1, ACC1, ALPP, tubulin overnight, and then applied with corresponding secondary antibodies the next day to detect the expression level of the corresponding protein.
  • HEK293T cells in good growth condition were added to a six-well plate and cultured at 37°C and 5% CO2 ;
  • Flag-SLC35F6 and GST-ALPP were transfected into HEK293T cells using PEI, and the medium was changed after 6 hours;
  • Immunoblotting was used to detect the levels of GST, p-AMPK, AMPK, and tubulin in cell line lysates and beads after immunoprecipitation.
  • Flag and GST represent overexpressed Flag-SLC35F6 and GST-ALPP. In the 5% input group, it represents the total content, and in the IP group, it represents the components pulled down by immunoprecipitation. The higher the ratio of IP/Input, the stronger the mutual binding. As shown in Figure 3, compared with the control group of Veh (containing only 1X PBS), the addition of UDP-GlcNAc increased p-AMPK, indicating that UDP-GlcNAc can enhance the activity of AMPK (compare the second and third lanes).
  • UDP-GlcNAc can reduce Flag-SLC35F6 after GST-ALPP immunoprecipitation by GST magnetic beads, indicating that UDP-GlcNAc can reduce the interaction between GST-ALPP and Flag-SLC35F6.
  • UDP-GlcNAc can enhance the activity of AMPK by reducing the interaction between SLC35F6 and ALPP.
  • HEK293T cells in good growth condition were added to a six-well plate and cultured at 37°C and 5% CO2;
  • the protein was detected by immunoblotting: polyacrylamide gel electrophoresis, electrophoresis parameters: constant voltage 80V, 20min plus 120V, 45min, then constant current 0.2A, 1h transfer, 5% skim milk blocking for 1h; incubated with primary antibodies p-AMPK, AMPK, p-ACC1, ACC1, SLC35F6, tubulin overnight, and then applied with corresponding secondary antibodies the next day to detect the expression level of the corresponding protein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)

Abstract

本申请公开了敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用，涉及生物技术领域。本申请发明人研究发现，SLC35F6能够作为AMPK活性调控的新靶点，并通过进一步研究发现，SLC35F6-ALPP复合体抑制AMPK的活性。本申请发现，敲低SLC35F6或ALPP能够激活AMPK，以SLC35F6或ALPP为目标，选取合适的siRNA，高效敲低SLC35F6或ALPP，为AMPK的激活提供新的技术方案。本申请首次明确了SLC35F6对AMPK活性调控作用，为与AMPK活性相关的疾病的诊断和治疗提供新的防治药物研发途径和药物作用靶点，具有十分重要的药用价值。

Description

敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用 技术领域
本申请涉及生物技术领域，具体涉及敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。
背景技术
AMPK(Adenosine 5‘-monophosphate(AMP)-activated protein kinase)即AMP依赖的蛋白激酶，是生物能量代谢调节的关键分子，广泛存在在动物和植物细胞中的蛋白质分子，是研究糖尿病及其他代谢相关疾病的核心。它表达于各种代谢相关的器官中，能被机体各种刺激激活，包括细胞压力、运动和很多激素及能影响细胞代谢的物质。AMPK作为一种营养和能量传感器，它可以感知细胞内ATP的水平高低。当线粒体被抑制，低能量供应条件下，AMPK磷酸化特异性的酶和位点，增加ATP生成，降低ATP消耗，以此来恢复能量平衡。
AMPK是代谢调节中最重要的激酶，当细胞内能量缺乏时，AMPK被上游激酶磷酸化激活，进而磷酸化许多代谢中的关键酶以及控制蛋白，促进分解代谢，抑制合成代谢，增加ATP的积累，为细胞提供能量。传统观点认为，AMPK的激活是由于细胞内AMP的浓度上升，与AMPK的γ亚基结合，改变AMPK异源三聚体的构象，使其α亚基的T172位点能够被上游激酶LKB1磷酸化，进而激活AMPK全酶。近年来的研究发现，AMPK的激活在不同的亚细胞区域并不一致，AMPK能够在溶酶体上激活，其溶酶体定位依赖于AMPKβ亚基的第二位甘氨酸的豆蔻酰化修饰。另外，除了响应AMP，溶酶体上的AMPK还能响应糖代谢次级产物FBP(果糖-1,6-二磷酸)的浓度变化。溶酶体上调控AMPK活性的蛋白，以及这些蛋白是否能够作为潜在的药物靶点，影响AMPK的活性，现在还不得而知。
现有的AMPK激活剂基于的调控机制主要集中在增加AMPKα的磷酸化，所涉及的调控位点已经饱和。目前还没有针对AMPK去磷酸化的机制，去探索和发现AMPK抑制剂和激活剂。
发明内容
本申请的目的在于克服现有技术的不足，提供敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。
为实现上述目的，本申请采取的技术方案为：SLC35F6在制备AMPK活性抑制剂中的应用。本申请的目的在于探索AMPK的溶酶体激活机制，进而发现新的AMPK活性调控蛋白。研究显示，溶酶体上的AMPK在能够感受糖代谢次级产物的变化，不同于整个细胞中的AMPK活性调控。所以，溶酶体上应该存在新的AMPK调节蛋白，能够更加直接的调控AMPK活性。本申请利用BiFC和临近标记技术，发现了SLC35F6-ALPP复合体在溶酶体上抑制AMPK的活性，而SLC35F6的配体UDP-GlcNAc能够解除SLC35F6-ALPP复合体对AMPK的抑制，进而激活AMPK，发挥疗效。
本申请还提供敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。
作为本申请所述应用的优选实施方式，所述试剂包括敲低SLC35F6基因表达的siRNA。
作为本申请所述应用的优选实施方式，所述siRNA的核苷酸序列如SEQ ID NO.1～SEQ ID NO.3任一项所示。
本申请还提供敲低或抑制ALPP的试剂在制备激活AMPK的药物中的应用。
作为本申请所述应用的优选实施方式，所述试剂包括敲低ALPP基因表达的siRNA。
作为本申请所述应用的优选实施方式，所述siRNA的核苷酸序列如SEQ ID NO.4～SEQ ID NO.6任一项所示。
本申请还提供一种AMPK激活剂，所述激活剂包括敲低SLC35F6的试剂和敲低ALPP的试剂中至少一种。
本申请还提供敲低SLC35F6的试剂和敲低ALPP的试剂中至少一种在制备预防和/或治疗肿瘤、炎症或糖尿病的产品中的应用。
作为本申请所述应用的优选实施方式，所述试剂包括UDP-GlcNAc。
本申请的有益效果：本申请提供敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。本申请发明人研究发现，SLC35F6能够作为AMPK活性调控的新靶点，并通过进一步研究发现，SLC35F6-ALPP复合体在溶酶体上抑 制AMPK的活性。本申请发现，敲低SLC35F6或ALPP能够激活AMPK，以SLC35F6或ALPP为目标，选取合适的siRNA，高效敲低SLC35F6或ALPP，为AMPK的激活提供新的技术方案。本申请首次明确了SLC35F6对AMPK活性调控作用，为与AMPK活性相关的疾病的诊断和治疗提供新的防治药物研发途径和药物作用靶点，具有十分重要的药用价值。
附图说明
图1为实施例1敲低SLC35F6后p-AMPK，AMPK，SLC35F6，tubulin的表达结果图；
图2为实施例2敲低ALPP后p-AMPK，AMPK，p-ACC1，ACC1，ALPP，tubulin的表达结果图；
图3为实施例3细胞裂解液和免疫沉淀后beads中GST，p-AMPK，AMPK，tubulin的表达结果图；
图4为实施例4敲低SLC35F6和饥饿处理后的p-AMPK，AMPK，p-ACC1，ACC1，SLC35F6，tubulin的表达结果图；
图5为实施例4敲低SLC35F6和H2O2处理后的p-AMPK，AMPK，p-ACC1，ACC1，SLC35F6，tubulin的表达结果图；
图6为实施例4敲低SLC35F6和AICAR处理后的p-AMPK，AMPK，p-ACC1，ACC1，SLC35F6，tubulin的表达结果图。
具体实施方式
以下通过实施例形式的具体实施方式，对本申请的上述内容再作进一步的详细说明。但不应将此理解为本申请上述主题的范围仅限于以下的实例。凡基于本申请上述内容所实现的技术均属于本申请的范围。
实施例1
本实施例通过实验验证敲低SLC35F6对AMPK活性的影响，具体实验步骤如下：
(1)将生长状态良好的HEK293T细胞加入六孔板中，于37℃，5％CO2培养；
(2)将终浓度为100nM对照siRNA(由广州锐博生物提供,货号#siN0000001-1-5)、100nM用于敲低SLC35F6的实验组siRNA分别与10ul的 RNAimax试剂、200ul的optimen混匀，得混合液；所述实验组siRNA的序列分别为：
实验组一(#1)：5′-GCAUGGUGUUGGACAGCUU-3′(SEQ ID NO:1)；
实验组二(#2)：5′-GCAUUGCCUUCUUCAACUU-3′(SEQ ID NO:2)；
实验组三(#3)：5′-GAGGAGAAGUUCGUCUACA-3′(SEQ ID NO:3)。
(3)将混合液室温静置20min后，加入六孔板的HEK293T细胞中，6小时后更换新鲜培养基；48h后，收集并裂解细胞，1000gx10min离心，收集上清，并提取蛋白。
(4)免疫印迹检测：将步骤(3)得到的蛋白进行聚丙烯酰胺凝胶电泳，电泳参数为：恒压80V，20min加上120v，45min，然后恒流0.2A，1h转膜，5％脱脂牛奶封闭1h；用一抗p-AMPK，AMPK，SLC35F6，tubulin孵育过夜，第二天再敷育对应的二抗，检测相应蛋白的表达水平。
实验结果如图1所示。p-AMPK(T172)表明AMKP的磷酸化程度，代表AMPK的活性。由图1可知看出，实验组没有表达SLC35F6，说明实验组成功敲低SLC35F6；对照组的p-AMPK的表达低于实验组，说明敲低SLC35F6后AMPK被激活。
实施例2
本实施例通过实验验证敲低ALPP对AMPK活性的影响，具体实验步骤如下：
(1)将生长状态良好的HEK293T细胞加入六孔板中，于37℃，5％CO2培养；
(2)将终浓度为100nM对照siRNA、100nM用于敲低ALPP的实验组siRNA分别与10ul的RNAimax试剂、200ul的optimen混匀，得混合液；所述实验组siRNA的序列分别为：
实验组一(#1)：5′-CUACGCAGCUCAUCUCCAA-3′(SEQ ID NO:4)；
实验组二(#2)：5′-CUGGAGACAUGAAAUACGA-3′(SEQ ID NO:5)；
实验组三(#3)：5′-CGGUCCUCCUAUACGGAAA-3′(SEQ ID NO:6)。
(3)将混合液室温静置20min后，加入六孔板的HEK293T细胞中，6小时后更换新鲜培养基；48h后，收集并裂解细胞，1000gx10min离心，收集上清，并提取蛋白。
(4)免疫印迹检测：将步骤(3)得到的蛋白进行聚丙烯酰胺凝胶电泳，电泳参数为：恒压80V，20min加上120v，45min，然后恒流0.2A，1h转膜，5％脱脂牛奶封闭1h；用一抗p-AMPK，AMPK，p-ACC1，ACC1，ALPP，tubulin孵育过夜，第二天再敷育对应的二抗，检测相应蛋白的表达水平。
实验结果如图2所示。由图2可知看出，实验组没有表达ALPP，说明实验组成功敲低ALPP；对照组的p-AMPK的表达低于实验组，说明敲低ALPP后AMPK被激活。
实施例3
本实施例通过实验验证降低SLC35F6和ALPP的相互作用对AMPK活性的影响，具体实验步骤如下：
(1)将生长状态良好的HEK293T细胞加入六孔板中，于37℃，5％CO2培养；采用PEI将Flag-SLC35F6和GST-ALPP顺转入HEK293T细胞，6小时后换液；
(2)48h后，裂解细胞，在细胞裂解液中加入UDP-GlcNAc孵育1h；
(3)2h后在裂解液中加入GST beads，旋转孵育2小时；
(4)beads沉淀后，用裂解液洗涤三次；
(5)采用免疫印迹检测细胞系裂解液和免疫沉淀后beads中GST，p-AMPK，AMPK，tubulin的水平。
实验结果如图3所示。Flag和GST代表过表达的Flag-SLC35F6和GST-ALPP。5％input组里面，代表总的含量，IP组里面，代表免疫共沉淀下拉下来的成分，IP/Input的比值越高，代表相互结合越强。由图3可知，相比于Veh的对照组(仅含有1X PBS)，UDP-GlcNAc的加入使得p-AMPK增加，表明UDP-GlcNAc能够提升AMPK的活性(对比第二泳道和第三泳道)。同时，UDP-GlcNAc能够降低GST磁珠免疫沉淀GST-ALPP过后的Flag-SLC35F6，表明UDP-GlcNAc能够降低GST-ALPP和Flag-SLC35F6的相互作用。综上，UDP-GlcNAc能够通过降低SLC35F6和ALPP的相互作用，进而提升AMPK的活性。
实施例4
本实施例验证敲低SLC35F6联合常规AMPK激活剂对AMPK活性的影响，具体实验步骤如下：
(1)将生长状态良好的HEK293T细胞加入六孔板中，于37℃，5％CO2培养；
(2)将终浓度为100nM对照siRNA、100mM用于敲低SLC35F6的实验组siRNA分别与10ul的RNAimax试剂、200ul的optimen混匀，得混合液；
(3)将混合液室温静置20min后，加入六孔板的HEK293T细胞中，6小时后更换新鲜培养基；
(4)48h后，分别进行饥饿处理：使用无葡萄糖培养基代替正常培养基16h、双氧水处理：正常培养的细胞中加入浓度为1mM的H2O2,5min、AICAR处理：正常培养的细胞中加入AMPK激活剂2mMAICAR4h；
(5)收集并裂解细胞，1000gx10min离心，收集上清，并提取蛋白；
(6)将蛋白进行免疫印迹检测：聚丙烯酰胺凝胶电泳，电泳参数：恒压80V，20min加上120v，45min，然后恒流0.2A，1h转膜，5％脱脂牛奶封闭1h；用一抗p-AMPK，AMPK，p-ACC1，ACC1，SLC35F6，tubulin孵育过夜，第二天再敷育对应的二抗，检测相应蛋白的表达水平。
结果如图4～6所示。由图4～6可知，采用常规AMPK激活剂(如葡萄糖饥饿16小时，双氧水处理5分钟，AMP类似物AICAR处理4小时)都能够提升AMPK的磷酸化(对比第一泳道和第二泳道)。敲低SLC35F6联合常规AMPK激活剂，能在本来已经激活的AMPK基础上更近一步激活(对比第二泳道和第四泳道)，由此表明敲低SLC35F6与常规AMPK激活剂联用能够更好的提升AMPK的活性。
最后应当说明的是，以上实施例仅用以说明本申请的技术方案而非对本申请保护范围的限制，尽管参照较佳实施例对本申请作了详细说明，本领域的普通技术人员应当理解，可以对本申请的技术方案进行修改或者等同替换，而不脱离本申请技术方案的实质和范围。

Claims (10)

  1. SLC35F6在制备AMPK活性抑制剂中的应用。
  2. 敲低或抑制SLC35F6的试剂在制备激活AMPK的药物中的应用。
  3. 根据权利要求2所述的应用，其特征在于，所述试剂包括敲低SLC35F6基因表达的siRNA。
  4. 根据权利要求3所述的应用，其特征在于，所述siRNA的核苷酸序列如SEQ ID NO.1～SEQ ID NO.3任一项所示。
  5. 敲低或抑制ALPP的试剂在制备激活AMPK的药物中的应用。
  6. 根据权利要求5所述的应用，其特征在于，所述试剂包括敲低ALPP基因表达的siRNA。
  7. 根据权利要求6所述的应用，其特征在于，所述siRNA的核苷酸序列如SEQ ID NO.4～SEQ ID NO.6任一项所示。
  8. 一种AMPK激活剂，其特征在于，所述激活剂包括敲低SLC35F6的试剂和敲低ALPP的试剂中至少一种。
  9. 敲低SLC35F6的试剂和敲低ALPP的试剂中至少一种在制备预防和/或治疗肿瘤、炎症或糖尿病的产品中的应用。
  10. 根据权利要求9所述的应用，其特征在于，所述试剂包括UDP-GlcNAc。
PCT/CN2023/108489 2023-06-15 2023-07-20 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用 Ceased WO2024254941A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310711086.8A CN116794325B (zh) 2023-06-15 2023-06-15 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用
CN202310711086.8 2023-06-15

Publications (1)

Publication Number Publication Date
WO2024254941A1 true WO2024254941A1 (zh) 2024-12-19

Family

ID=88039073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/108489 Ceased WO2024254941A1 (zh) 2023-06-15 2023-07-20 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Country Status (2)

Country Link
CN (1) CN116794325B (zh)
WO (1) WO2024254941A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116794325B (zh) * 2023-06-15 2024-05-10 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045543A2 (en) * 2002-11-14 2004-06-03 Dharmacon, Inc. Functional and hyperfunctional sirna
US20090182134A1 (en) * 2002-11-14 2009-07-16 Dharmacon, Inc. siRNA targeting phosphatases
KR20220087022A (ko) * 2020-12-17 2022-06-24 주식회사 초메디신 뇌종양 진단 또는 예후 예측용 용질 운반체 바이오마커 조성물
CN116794325A (zh) * 2023-06-15 2023-09-22 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050058530A (ko) * 2003-12-12 2005-06-17 주식회사 엠디바이오알파 5' 에이엠피-활성화 단백질 인산화 효소 활성 증진 물질의스크리닝 방법
AU2014200497A1 (en) * 2007-01-16 2014-02-20 Ipintl, Llc Novel Composition for Treating Metabolic Syndrome
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CN102026672A (zh) * 2008-03-12 2011-04-20 肿瘤疗法科学股份有限公司 C2orf18作为癌症治疗和诊断的靶基因
KR20120051173A (ko) * 2010-11-12 2012-05-22 경희대학교 산학협력단 Ａｍｐｋ 활성화제
EP3060650A4 (en) * 2013-10-25 2017-04-19 Agency For Science, Technology And Research Culturing pluripotent stem cells
CA2836750A1 (en) * 2013-12-17 2015-06-17 Agada Biosciences, LLC Method and agents to quantify proteins from tissues
WO2017052340A1 (ko) * 2015-09-25 2017-03-30 고려대학교 산학협력단 운동유사효과 유도용 약학 조성물
CN108079315B (zh) * 2016-11-21 2021-09-24 厦门华绰生物医药科技有限公司 FBP aldolase在制备激活AMPK的药物中的用途
KR101905726B1 (ko) * 2017-03-13 2018-10-08 연세대학교 산학협력단 카월을 유효성분으로 포함하는 ampk 활성 조절용 조성물
KR101925020B1 (ko) * 2017-04-21 2018-12-04 연세대학교 산학협력단 Mkrn1의 발현 또는 활성 억제제를 유효성분으로 함유하는, 대사성 질환의 예방 및 치료용 약학적 조성물
CN110179985A (zh) * 2019-05-17 2019-08-30 中山大学 端粒结合蛋白hp1bp3在制备肿瘤细胞调控剂中的应用
CN115869339A (zh) * 2022-10-31 2023-03-31 中山大学附属第一医院 铜螯合剂与ampk激活剂联合用于制备肿瘤治疗药物的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045543A2 (en) * 2002-11-14 2004-06-03 Dharmacon, Inc. Functional and hyperfunctional sirna
US20090182134A1 (en) * 2002-11-14 2009-07-16 Dharmacon, Inc. siRNA targeting phosphatases
KR20220087022A (ko) * 2020-12-17 2022-06-24 주식회사 초메디신 뇌종양 진단 또는 예후 예측용 용질 운반체 바이오마커 조성물
CN116794325A (zh) * 2023-06-15 2023-09-22 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENG MINGHUI : "Research Progress on Mechanisms of AMPK in Diabetes Prevention and Control", CHINESE PHARMACOLOGICAL BULLETIN, vol. 37, no. 9, 26 August 2021 (2021-08-26), pages 1208 - 1212, XP093248550 *
XIAOYAN PAN, MARTIN WILSON, LADAN MIRBAHAI, CARMEL MCCONVILLE, THEODOROS N. ARVANITIS, JULIAN L. GRIFFIN, RISTO A. KAUPPINEN, ANDR: "In Vitro Metabonomic Study Detects Increases in UDP-GlcNAc and UDP-GalNAc, as Early Phase Markers of Cisplatin Treatment Response in Brain Tumor Cells", JOURNAL OF PROTEOME RESEARCH, AMERICAN CHEMICAL SOCIETY, vol. 10, no. 8, 5 August 2011 (2011-08-05), pages 3493 - 3500, XP055137817, ISSN: 15353893, DOI: 10.1021/pr200114v *
XUAN LINGLING , QI HOU: "Recent advances in the study of AMPK and inflammatory pulmonary disease", ACTA PHARMACEUTICA SINICA, vol. 49, no. 8, 12 August 2014 (2014-08-12), pages 1089 - 1096, XP093248545, DOI: 10.16438/j.0513-4870.2014.08.011 *
ZHAO, SONGYUAN ET AL.: "New Progress of AMPK in Cancer Research", INTERNATIONAL JOURNAL OF DIGESTIVE DISEASES, vol. 33, no. 2, 30 April 2013 (2013-04-30), CN, pages 101 - 104, 108, XP009559365, ISSN: 1673-534X, DOI: 10.3969/j.issn.1673-534X.2013.02.009 *

Also Published As

Publication number Publication date
CN116794325A (zh) 2023-09-22
CN116794325B (zh) 2024-05-10

Similar Documents

Publication Publication Date Title
Si et al. Methyltransferase 3 mediated miRNA m6A methylation promotes stress granule formation in the early stage of acute ischemic stroke
Suizu et al. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt
Funabiki et al. Making an effective switch at the kinetochore by phosphorylation and dephosphorylation
Sharma et al. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway
Zachara et al. The dynamic stress-induced “O-GlcNAc-ome” highlights functions for O-GlcNAc in regulating DNA damage/repair and other cellular pathways
Langin et al. Importance of TNFα and neutral lipases in human adipose tissue lipolysis
Gaudillière et al. A CaMKII-NeuroD signaling pathway specifies dendritic morphogenesis
Horiuchi et al. Taking on challenging targets: making MYC druggable
Shahbazian et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity
Shum et al. Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice
Kang et al. Phosphorylation-facilitated sumoylation of MEF2C negatively regulates its transcriptional activity
Fang et al. Cdk5-mediated phosphorylation of Axin directs axon formation during cerebral cortex development
Schneider et al. The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation
Wang et al. microRNA‐135a protects against myocardial ischemia‐reperfusion injury in rats by targeting protein tyrosine phosphatase 1B
Mao et al. MicroRNA-19b mediates lung epithelial-mesenchymal transition via phosphatidylinositol-3, 4, 5-trisphosphate 3-phosphatase in response to mechanical stretch
Mohan et al. PI3K/mTOR signaling pathways in medulloblastoma
CN116794325B (zh) 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用
Li et al. Increased sensitivity of DNA damage response-deficient cells to stimulated microgravity-induced DNA lesions
Ding et al. The role of H3K9me2‐regulated base excision repair genes in the repair of DNA damage induced by arsenic in HaCaT cells and the effects of Ginkgo biloba extract intervention
Wang et al. Biochemical and biological characterization of a neuroendocrine‐associated phosphatase
TW201818959A (zh) Fbp aldolase在製備啟動ampk的藥物中的用途
Schmitt et al. ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells
Zhang et al. The role of lactate metabolism in retinoblastoma tumorigenesis and ferroptosis resistance
Zhong et al. TGF-β secreted by cancer cells-platelets interaction activates cancer metastasis potential by inducing metabolic reprogramming and bioenergetic adaptation
Tian et al. miR-218 inhibits glucose metabolism in non-small cell lung cancer via the NF-κB signaling pathway

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23941169

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE